This Week in Wellworthy: Pfizer’s $7B deal shows how profit drives obesity research while women’s health lags behind

September 24, 2025

Every week, we track the biggest health policy and access stories shaping your care, your wallet, and your plate. Here’s what you need to know:

Pfizer’s $7B deal shows how profit drives obesity research while women’s health lags behind

This week’s health headlines show a clear divide: when solutions make money, they move fast. But when they mostly affect women, equity, or everyday food access, they often get sidelined. Here’s what you need to know.

Obesity Drugs:

Pfizer just bought Metsera in a deal worth up to $7.3B, jumping back into the weight-loss race after pulling its own candidate. Obesity drugs matter, they reduce risks of diabetes, heart disease, and more, but pharma’s billions show who sets the pace.

Fibroids:

Affect 26 million U.S. women, cost ~$34B/year, yet NIH invests only $17M annually (0.05% of its budget). Black women are disproportionately impacted and more likely to be offered a hysterectomy as the first treatment option.

Funding Gaps:

PCOS, endometriosis, and other women’s health conditions face similar underfunding, showing how advocacy and visibility shape research dollars.

The Bigger Picture:

Obesity meds can help individuals, but without tackling food deserts, SNAP access, safe spaces to move, and systemic inequities, the epidemic will persist.

This Week’s Bright Spot

Change is People Led

Real change doesn’t start at the top; it starts with people demanding it. HIV, breast cancer, long COVID all got research and policy attention because communities pushed. You have power, whether that’s sharing your story, supporting food banks, or backing advocacy for women’s health funding.

Access Community Resources

We’re building a state-by-state resource hub with vaccine info, SNAP/WIC access, food bank directories, and insurer contacts.

Your input helps make this stronger. If you know a resource that’s helping your community, please share it so others can benefit too.

P.S. – This is an archive of our weekly email. If you’d like to see the email with full content and special offers, please consider subscribing to our newsletter.

References & Further Reading

  • Newsweek. Fibroids Affect Millions, So Why Do Many Women Still Wait Years for Treatment. Sept 18, 2025.
  • Reuters. Pfizer to Buy Weight-Loss Drug Developer Metsera. Sept 22, 2025.
  • CDC. Adult Obesity Facts. Updated 2024.
  • NIH Categorical Spending Database. Research Spending by Condition, 2022–2024.
  • NCBI Bookshelf. Uterine Fibroids – Research Gaps. 2024.
  • StatNews. Trump Autism Action Plan, Tylenol Link, Leucovorin Treatment. Sept 22, 2025.
  • Medical News Today. Poor Sleep Linked to 172 Diseases. Aug 4, 2025.
  • Medscape. Myo-Inositol Fails to Reduce Pregnancy Complications in Women with PCOS. Sept 2025.
  • UCSF News. Big Data Begins to Crack the Case of Endometriosis. July 2025.